_id
690da85cccc777a4e85d07d8
Ticker
ABPWW
Name
Abpro Holdings Inc
Exchange
NASDAQ
Address
68 Cummings Park Drive, Woburn, MA, United States, 01801
Country
USA
Sector
Industry
Currency
USD
Website
https://abpro.co
Description
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Last Close
0.0161
Volume
2311
Current Price
0.0149
Change
0.0013
Last Updated
2026-01-21T19:05:36.266Z
Image
data:image/webp;base64,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
Ipo Date
2022-03-07T00:00:00.000Z
Market Cap
-
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
1336000
Operating Income
-1336000
Interest Expense
193000
Pretax Income
-1657000
Net Income
-1657000
Eps
-0.6200832116493316
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
-
EBITDA
-1323000
Operating Margin
-
Total Other Income Expense Net
-321000
Cash
343000
Short Term Investments
-
Receivables
271000
Inventories
-
Total Current Assets
1225000
Property Plant Equipment
0
Total Assets
1703000
Payables
4724000
Short Term Debt
147000
Long Term Debt
-
Total Liabilities
17298000
Equity
-16143999
Bs_currency_symbol
USD
Depreciation
141000
Change In Working Capital
-1352000
Cash From Operations
-2281000
Capital Expenditures
0
Cash From Investing
26000
Cash From Financing
569000
Net Change In Cash
-1686000
Cf_currency_symbol
USD
PE
-
PB
-0.0024663101007377417
ROE
10.263875759655336
ROA
-97.29888432178508
FCF
-2281000
Fcf Percent
-
Piotroski FScore
1
Health Score
23
Deep Value Investing Score
0.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
1
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
0
Quality Investing Score
1.5
Value Investing Score
2
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
1336000
Quarters > 0 > income Statement > operating Income
-1336000
Quarters > 0 > income Statement > interest Expense
193000
Quarters > 0 > income Statement > pretax Income
-1657000
Quarters > 0 > income Statement > net Income
-1657000
Quarters > 0 > income Statement > eps
-0.6200832116493316
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
2672222
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-1323000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-321000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
343000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
271000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
1225000
Quarters > 0 > balance Sheet > property Plant Equipment
0
Quarters > 0 > balance Sheet > total Assets
1703000
Quarters > 0 > balance Sheet > payables
4724000
Quarters > 0 > balance Sheet > short Term Debt
147000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
17298000
Quarters > 0 > balance Sheet > equity
-16143999
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-1657000
Quarters > 0 > cash Flow > depreciation
141000
Quarters > 0 > cash Flow > change In Working Capital
-1352000
Quarters > 0 > cash Flow > cash From Operations
-2281000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
26000
Quarters > 0 > cash Flow > cash From Financing
569000
Quarters > 0 > cash Flow > net Change In Cash
-1686000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.6200832116493316
Quarters > 0 > ratios > PB
-0.0024663101007377417
Quarters > 0 > ratios > ROE
10.263875759655336
Quarters > 0 > ratios > ROA
-97.29888432178508
Quarters > 0 > ratios > FCF
-2281000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
23
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
143000
Quarters > 1 > income Statement > gross Profit
-143000
Quarters > 1 > income Statement > operating Expenses
2118000
Quarters > 1 > income Statement > operating Income
-2261000
Quarters > 1 > income Statement > interest Expense
174000
Quarters > 1 > income Statement > pretax Income
-2984000
Quarters > 1 > income Statement > net Income
-2984000
Quarters > 1 > income Statement > eps
-0.05187997179078692
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
57517379
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-2667000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-723000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
2014000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
342000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
3068000
Quarters > 1 > balance Sheet > property Plant Equipment
164000
Quarters > 1 > balance Sheet > total Assets
3483000
Quarters > 1 > balance Sheet > payables
5266000
Quarters > 1 > balance Sheet > short Term Debt
2225000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
20430000
Quarters > 1 > balance Sheet > equity
-17496000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-2984000
Quarters > 1 > cash Flow > depreciation
143000
Quarters > 1 > cash Flow > change In Working Capital
483000
Quarters > 1 > cash Flow > cash From Operations
-1386000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
2010000
Quarters > 1 > cash Flow > net Change In Cash
624000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.05187997179078692
Quarters > 1 > ratios > PB
-0.048983135979652495
Quarters > 1 > ratios > ROE
17.05532693187014
Quarters > 1 > ratios > ROA
-85.6732701693942
Quarters > 1 > ratios > FCF
-1386000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
27
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
152000
Quarters > 2 > income Statement > gross Profit
-152000
Quarters > 2 > income Statement > operating Expenses
2806000
Quarters > 2 > income Statement > operating Income
-2958000
Quarters > 2 > income Statement > interest Expense
737000
Quarters > 2 > income Statement > pretax Income
-3887000
Quarters > 2 > income Statement > net Income
-3887000
Quarters > 2 > income Statement > eps
-0.07633242999096658
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
50922000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-2998000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-929000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
1405000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
331000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
2219000
Quarters > 2 > balance Sheet > property Plant Equipment
306000
Quarters > 2 > balance Sheet > total Assets
2797000
Quarters > 2 > balance Sheet > payables
4704000
Quarters > 2 > balance Sheet > short Term Debt
3248000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
20608000
Quarters > 2 > balance Sheet > equity
-18360000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-3887000
Quarters > 2 > cash Flow > depreciation
152000
Quarters > 2 > cash Flow > change In Working Capital
504000
Quarters > 2 > cash Flow > cash From Operations
-1719000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-29638990
Quarters > 2 > cash Flow > cash From Financing
132000
Quarters > 2 > cash Flow > net Change In Cash
-1587000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.07633242999096658
Quarters > 2 > ratios > PB
-0.04132558823529412
Quarters > 2 > ratios > ROE
21.17102396514161
Quarters > 2 > ratios > ROA
-138.97032534858778
Quarters > 2 > ratios > FCF
-1719000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
30
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
183000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
183000
Quarters > 3 > income Statement > operating Expenses
8178000
Quarters > 3 > income Statement > operating Income
-7995000
Quarters > 3 > income Statement > interest Expense
387000
Quarters > 3 > income Statement > pretax Income
-5509000
Quarters > 3 > income Statement > net Income
-5509000
Quarters > 3 > income Statement > eps
-0.6745438961675033
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
8167000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-5180000
Quarters > 3 > income Statement > operating Margin
-4368.852459016393
Quarters > 3 > income Statement > total Other Income Expense Net
2486000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
2850000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
323000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
3776000
Quarters > 3 > balance Sheet > property Plant Equipment
455000
Quarters > 3 > balance Sheet > total Assets
4661000
Quarters > 3 > balance Sheet > payables
3936000
Quarters > 3 > balance Sheet > short Term Debt
3328000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
19607000
Quarters > 3 > balance Sheet > equity
-15495000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-5509325
Quarters > 3 > cash Flow > depreciation
-
Quarters > 3 > cash Flow > change In Working Capital
-2524439
Quarters > 3 > cash Flow > cash From Operations
-8254008
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-29638990
Quarters > 3 > cash Flow > cash From Financing
40274939
Quarters > 3 > cash Flow > net Change In Cash
2978403
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.6745438961675033
Quarters > 3 > ratios > PB
-0.007853391416585996
Quarters > 3 > ratios > ROE
35.55340432397547
Quarters > 3 > ratios > ROA
-118.19352070371166
Quarters > 3 > ratios > FCF
-8254008
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-45.103868852459016
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
183000
Annuals > 0 > income Statement > cost Of Revenue
665000
Annuals > 0 > income Statement > gross Profit
-482000
Annuals > 0 > income Statement > operating Expenses
9439000
Annuals > 0 > income Statement > operating Income
-9921000
Annuals > 0 > income Statement > interest Expense
387000
Annuals > 0 > income Statement > pretax Income
-7232000
Annuals > 0 > income Statement > net Income
-7232000
Annuals > 0 > income Statement > eps
-0.3089278086287911
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
23410000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-6180000
Annuals > 0 > income Statement > operating Margin
-5421.311475409836
Annuals > 0 > income Statement > total Other Income Expense Net
2689000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
2850000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
323000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
3776000
Annuals > 0 > balance Sheet > property Plant Equipment
455000
Annuals > 0 > balance Sheet > total Assets
4661000
Annuals > 0 > balance Sheet > payables
3936000
Annuals > 0 > balance Sheet > short Term Debt
3328000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
19607000
Annuals > 0 > balance Sheet > equity
-15495000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-7232000
Annuals > 0 > cash Flow > depreciation
622000
Annuals > 0 > cash Flow > change In Working Capital
-1319000
Annuals > 0 > cash Flow > cash From Operations
-9030000
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
11161000
Annuals > 0 > cash Flow > net Change In Cash
2131000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-0.3089278086287911
Annuals > 0 > ratios > PB
-0.02251106808647951
Annuals > 0 > ratios > ROE
46.67312036140691
Annuals > 0 > ratios > ROA
-155.1598369448616
Annuals > 0 > ratios > FCF
-9030000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-49.34426229508197
Annuals > 0 > health Score
31
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
122000
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
122000
Annuals > 1 > income Statement > operating Expenses
11868000
Annuals > 1 > income Statement > operating Income
-11746000
Annuals > 1 > income Statement > interest Expense
23000
Annuals > 1 > income Statement > pretax Income
-11706000
Annuals > 1 > income Statement > net Income
-11706000
Annuals > 1 > income Statement > eps
-0.7230389129092032
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
16190000
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-10891000
Annuals > 1 > income Statement > operating Margin
-9627.868852459016
Annuals > 1 > income Statement > total Other Income Expense Net
40000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
723000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
88000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
2035000
Annuals > 1 > balance Sheet > property Plant Equipment
1068000
Annuals > 1 > balance Sheet > total Assets
3355000
Annuals > 1 > balance Sheet > payables
7916000
Annuals > 1 > balance Sheet > short Term Debt
2439000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
91790000
Annuals > 1 > balance Sheet > equity
-88984000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-11706000
Annuals > 1 > cash Flow > depreciation
792000
Annuals > 1 > cash Flow > change In Working Capital
1207000
Annuals > 1 > cash Flow > cash From Operations
-7402000
Annuals > 1 > cash Flow > capital Expenditures
48000
Annuals > 1 > cash Flow > cash From Investing
-48000
Annuals > 1 > cash Flow > cash From Financing
849000
Annuals > 1 > cash Flow > net Change In Cash
-6601000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.7230389129092032
Annuals > 1 > ratios > PB
-0.002710948035601906
Annuals > 1 > ratios > ROE
13.15517396385867
Annuals > 1 > ratios > ROA
-348.9120715350224
Annuals > 1 > ratios > FCF
-7450000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-61.0655737704918
Annuals > 1 > health Score
25
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
2029000
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
2029000
Annuals > 2 > income Statement > operating Expenses
18714000
Annuals > 2 > income Statement > operating Income
-16685000
Annuals > 2 > income Statement > interest Expense
248000
Annuals > 2 > income Statement > pretax Income
-16885000
Annuals > 2 > income Statement > net Income
-17215000
Annuals > 2 > income Statement > eps
-0.4590666666666667
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
37500000
Annuals > 2 > income Statement > income Tax Expense
330000
Annuals > 2 > income Statement > EBITDA
-15781000
Annuals > 2 > income Statement > operating Margin
-822.3262690980779
Annuals > 2 > income Statement > total Other Income Expense Net
-200000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
7325000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
2030000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
9647000
Annuals > 2 > balance Sheet > property Plant Equipment
1802000
Annuals > 2 > balance Sheet > total Assets
11852000
Annuals > 2 > balance Sheet > payables
8152000
Annuals > 2 > balance Sheet > short Term Debt
755000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
87586000
Annuals > 2 > balance Sheet > equity
-76283000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-17215000
Annuals > 2 > cash Flow > depreciation
856000
Annuals > 2 > cash Flow > change In Working Capital
3389000
Annuals > 2 > cash Flow > cash From Operations
-8952000
Annuals > 2 > cash Flow > capital Expenditures
65000
Annuals > 2 > cash Flow > cash From Investing
-65000
Annuals > 2 > cash Flow > cash From Financing
9784000
Annuals > 2 > cash Flow > net Change In Cash
767000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.4590666666666667
Annuals > 2 > ratios > PB
-0.007324698818871833
Annuals > 2 > ratios > ROE
22.567282356488338
Annuals > 2 > ratios > ROA
-145.24974687816405
Annuals > 2 > ratios > FCF
-9017000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-4.444061113849187
Annuals > 2 > health Score
31
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
-
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
1793
Annuals > 3 > income Statement > operating Income
-1793
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-1793
Annuals > 3 > income Statement > net Income
-1793
Annuals > 3 > income Statement > eps
-0.00004781333333333333
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
37500000
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-1793
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
-
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
-
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
-
Annuals > 3 > balance Sheet > payables
-
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
-
Annuals > 3 > balance Sheet > equity
-
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-
Annuals > 3 > cash Flow > depreciation
-
Annuals > 3 > cash Flow > change In Working Capital
-
Annuals > 3 > cash Flow > cash From Operations
-
Annuals > 3 > cash Flow > capital Expenditures
-
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
-
Annuals > 3 > cash Flow > net Change In Cash
-
Annuals > 3 > cash Flow > currency_symbol
-
Annuals > 3 > ratios > PE
-0.00004781333333333333
Annuals > 3 > ratios > PB
-
Annuals > 3 > ratios > ROE
-
Annuals > 3 > ratios > ROA
-
Annuals > 3 > ratios > FCF
-
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
39
Valuation > metrics > PE
-0.6200832116493316
Valuation > metrics > PB
-0.0024663101007377417
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
10.263875759655336
Profitability > metrics > ROA
-135.26530612244898
Profitability > metrics > Net Margin
-
Profitability > final Score
21
Profitability > verdict
Weak
Risk > metrics > Debt Equity
-
Risk > metrics > Interest Coverage
-6.922279792746114
Risk > final Score
2
Risk > verdict
High
Liquidity > metrics > Current Ratio
-
Liquidity > metrics > Quick Ratio
-
Liquidity > final Score
50
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
34
Prev Profitabilities > 1
40
Prev Profitabilities > 2
40
Prev Risks > 0
-22
Prev Risks > 1
14
Prev Risks > 2
-53
Prev Liquidities > 0
50
Prev Liquidities > 1
50
Prev Liquidities > 2
50
Updated At
2026-01-21T19:05:36.983Z
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAug Wrap: Is Park Ohio Holdings Corp a play on infrastructure spending - Market Volume Summary & Reliable Volume Spike Trade Alerts baoquankhu1.vn
Read more →Aug Big Picture: Why is COLB stock going up - Portfolio Profit Report & Free Risk Controlled Daily Trade Plans baoquankhu1.vn
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Abpro Holdings Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.